| Literature DB >> 27267016 |
Nathan B Sautter1, Timothy L Smith2.
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an incidence of 1:5000. Recurrent, spontaneous epistaxis is the most common presenting symptom. Severity of epistaxis varies widely, from mild, self-limited nosebleeds to severe, life-threatening nasal hemorrhage. Treatment of HHT-related epistaxis presents a challenge to the otolaryngologist due to the recurrent, persistent nature of epistaxis often requiring multiple treatments. Treatment modalities range from conservative topical therapies to more aggressive surgical treatments.Entities:
Keywords: Bevacizumab; Epistaxis; Hereditary hemorrhagic telangiectasia (HHT); Laser photocoagulation; Osler-Weber-Rendu; Septodermoplasty; Young’s procedure
Mesh:
Substances:
Year: 2016 PMID: 27267016 DOI: 10.1016/j.otc.2016.02.010
Source DB: PubMed Journal: Otolaryngol Clin North Am ISSN: 0030-6665 Impact factor: 3.346